• Kit73 – relatórios preliminares dos padrões de terapia imunossupressora em uma coorte de pacientes pós-transplante renal no Brasil

  • Voltar

Título

Kit73 - relatórios preliminares dos padrões de terapia imunossupressora em uma coorte de pacientes pós-transplante renal no Brasil

Tipo de documento

Apresentação

Descrição

Resumo apresentado na The Professional Society for Health Economics and Outcomes Research (ISPOR)

Fonte

ISPOR

Ano de publicação

2011

Referência (Vancouver)

Carvalho DDBM, Garcia V, Abbud-Filho M, Nishikawa AM, Asano E, Nita ME, Szabo SM, Levy AR, Carvalho JF, Donato BM, Rahal E. Kit73- preliminary reports of immunosupressant therapy patterns in a cohort of post kidney transplant patients in Brazil [Internet]. In: ISPOR 2011; Baltimore, MD, USA. Disponível em: https\://www\.ispor.org/heor-resources/presentations-database/presentation/ispor-16th-annual-international-meeting/kit73-preliminary-reports-of-immunosupressant-therapy-patterns-in-a-cohort-of-post-kidney-transplant-patients-in-brazil

URL

https://www.ispor.org/heor-resources/presentations-database/presentation/ispor-16th-annual-international-meeting/kit73-preliminary-reports-of-immunosupressant-therapy-patterns-in-a-cohort-of-post-kidney-transplant-patients-in-brazil

Identificador

2011ISPOR061

Title

Kit73- Preliminary Reports of Immunosupressant Therapy Patterns in a Cohort of Post Kidney Transplant Patients in Brazil.

Document type

Presentation

Description

Abstract presented at The Professional Society for Health Economics and Outcomes Research (ISPOR)

Source

ISPOR

Publication year

2011

Reference (Vancouver)

Carvalho DDBM, Garcia V, Abbud-Filho M, Nishikawa AM, Asano E, Nita ME, Szabo SM, Levy AR, Carvalho JF, Donato BM, Rahal E. Kit73- preliminary reports of immunosupressant therapy patterns in a cohort of post kidney transplant patients in Brazil [Internet]. In: ISPOR 2011; Baltimore, MD, USA. Available from: https\://www\.ispor.org/heor-resources/presentations-database/presentation/ispor-16th-annual-international-meeting/kit73-preliminary-reports-of-immunosupressant-therapy-patterns-in-a-cohort-of-post-kidney-transplant-patients-in-brazil

URL

https://www.ispor.org/heor-resources/presentations-database/presentation/ispor-16th-annual-international-meeting/kit73-preliminary-reports-of-immunosupressant-therapy-patterns-in-a-cohort-of-post-kidney-transplant-patients-in-brazil

Identifier

2011ISPOR061

Resumo

Objetivos: O objetivo deste estudo foi caracterizar os padrões específicos de tratamento com imunossupressores (IS) no Brasil entre pacientes submetidos a transplante renal. Métodos: Revisão médica não intervencionista, multicêntrica dos prontuários médicos de pacientes submetidos a transplante renal. Dados de acompanhamento de cinco anos sobre o uso de medicamentos IS de adultos (≥18 anos na época do transplante) com transplantes de rim único realizados de janeiro de 2004 a janeiro de 2005 foram coletados de 7 centros de transplante em hospitais Brasileiros. Os pacientes foram censurados em caso de perda do enxerto ou perda de acompanhamento. Resultados: Dados de 498 pacientes foram incluídos; 51,2% eram do sexo feminino, a idade média era 38,9±13,9 anos e 55,4% eram receptores de rins de doadores falecidos. Dos 498 pacientes, 61,2% foram tratados com regimes de IS baseados em tacrolimus (TAC) como inibidor de calcineurina (CNI) inicial, enquanto 38,8% foram tratados com ciclosporina (CyC). A troca de CNI de TAC para CyC ocorreu em 4,6%, contra 5,6% que trocaram de CyC para TAC. Houve uma tendência de diminuição da dose média de CNI ao longo dos anos: ao final do primeiro ano, a dose média de TAC era 9,3±5,4 mg/dia e 282,1±118,3 mg/dia para CyC, diminuindo para 5,2±3,6 e 158,7±57,8 mg/dia no terceiro ano, e 4,8±7,3 e 144,2±58,4 mg/dia no quinto ano. Ao final do primeiro (n=455) e segundo ano (n=408) pós-transplante, os regimes de IS mais comuns foram TAC/prednisona/mycophenolate mofetil (MMF) (19,1% em ambos os anos), TAC/prednisona/azatioprina (15,6% no primeiro ano e 14,7% no segundo ano) e CyC/prednisona/azatioprina (13,2% no primeiro ano e 14,0% no segundo ano). No final do quinto ano (n=141), no entanto, o regime de IS mais comum foi TAC/prednisona/mycophenolate sódico (MFS; 31,9%), seguido por CyC/prednisona/MFS (7,8%) e TAC/prednisona/MMF (7,1%). Conclusões: Tacrolimus foi o CNI de escolha para a maioria dos pacientes de transplante renal de novo em 2004. Os principais regimes de terapia IS durante os primeiros anos pós-transplante foram tacrolimus/prednisona/mycophenolate mofetil.

Notas

O registro foi originalmente publicado em inglês. A versão em português foi traduzida com o apoio de inteligência artificial.

Abstract

Objetives: The aim of this study was to characterize Brazilian-specific immunosuppressant (IS) treatment patterns among kidney transplant patients. Methods: Non-interventional, multicenter, medical chart review of patients undergoing kidney transplant. Five year follow-up data on IS medication use from adult (≥ 18 years old at time of transplantation), single kidney only transplants from Jan/2004 to Jan/2005 were collected from 7 transplant center in Brazilian hospitals. Patients were censored on graft loss or loss of follow-up. Results: Data on 498 patients were included; 51.2% were female, the , average age was 38.9±13.9 years, and 55.4% was recipients of kidneys from deceased donors. Of the 498 patients, 61.2% were treated with tacrolimus (TAC)-based IS regimens as the initial calcineurin inhibitor (CNI), while 38.8% were treated with cyclosporine (CyC). CNI switching from TAC to CyC occurred in 4.6%, versus 5.6% that switched from CyC to TAC. There was a decreasing trend in average CNI dose by year: at the end of the first year, the mean dose of TAC was 9.3±5.4 mg/day and 282.1±118.3 mg/day for CYC, decreasing to 5.2±3.6 and 158.7±57.8 mg/day in the third year, and 4.8±7.3 and 144.2±58.4 mg/day in the fifth year. At the end of the first (n=455) and second year (n=408) post-transplant, the most common IS regimens were TAC/prednisone/mycophenolate mophetil (MMF) (19.1% in both years), TAC/prednisone/azathioprine (15.6% at first year and 14.7% at second year) and CyC/prednisone/azathioprine (13.2% at first year and 14.0% at second year). By the end of the fifth year (n=141), however, the most common IS regimen was TAC/prednisone/mycophenolate sodium (MFS; 31.9%), followed by CyC/prednisone/MFS (7.8%) and TAC/prednisone/MMF (7.1%). Conclusions: Tacrolimus was the CNI of choice for the majority of de novo kidney transplant patients in 2004. The main IS therapy regimens during the first post-transplant years was tacrolimus/prednisone/mycophenolate mophetil.

Notes

The record was originally published in English. The Portuguese version was translated with the aid of artificial intelligence.

Continuar navegando